Navidea Reports Second Quarter 2015 Financial Results; Reiterates 2015 Lymphoseek® Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Navidea Biopharma (NAVB) Misses Q2 EPS by 2c
July 30, 2015 7:36 AM EDTNavidea Biopharma (NYSE: NAVB) reported Q2 EPS of ($0.06), $0.02 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $2.9 million versus the consensus estimate of $2.18 million.
Specific events and milestones achieved since the beginning of the second quarter include the following:
Commercial
Achieved sequential quarter-on-quarter Lymphoseek revenue growth and continued improvement in key performance indicators;Fully deployed a Lymphoseek-dedicated field force mid-second quarter;Exercised pricing... More